...
首页> 外文期刊>Oncogene >Identification of phosphorylase kinase as a novel therapeutic target through high-throughput screening for anti-angiogenesis compounds in zebrafish
【24h】

Identification of phosphorylase kinase as a novel therapeutic target through high-throughput screening for anti-angiogenesis compounds in zebrafish

机译:通过高通量筛选斑马鱼中抗血管生成化合物,鉴定磷酸化酶激酶为新型治疗靶标

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Angiogenesis is essential for development and tumor progression. With the aim of identifying new compound inhibitors of the angiogenesis process, we used an established enhanced green fluorescent protein-transgenic zebrafish line to develop an automated assay that enables high-throughput screening of compound libraries in a whole-organism setting. Using this system, we have identified novel kinase inhibitor compounds that show anti-angiogenic properties in both zebrafish in-vivo system and in human endothelial cell in-vitro angiogenesis models. Furthermore, we have determined the kinase target of these compounds and have identified and validated a previously uncharacterized involvement of phosphorylase kinase subunit G1 (PhKG1) in angiogenesis in vivo . In addition, we have found that PhKG1 is upregulated in human tumor samples and that aberrations in gene copy number of PhK subunits are a common feature of human tumors. Our results provide a novel insight into the angiogenesis process, as well as identify new potential targets for anti-angiogenic therapies.
机译:血管生成对于发育和肿瘤进展至关重要。为了确定新的血管生成过程化合物抑制剂,我们使用了已建立的增强型绿色荧光蛋白转基因斑马鱼品系来开发自动化分析方法,该方法能够在整个生物环境中对化合物文库进行高通量筛选。使用该系统,我们已经鉴定了在斑马鱼体内系统和人内皮细胞体外血管生成模型中均显示出抗血管生成特性的新型激酶抑制剂化合物。此外,我们已经确定了这些化合物的激酶靶标,并且已经鉴定并验证了磷酸化酶激酶亚基G1(PhKG1)在体内血管生成中的先前未表征的参与。另外,我们已经发现在人类肿瘤样品中PhKG1被上调,并且PhK亚基的基因拷贝数异常是人类肿瘤的共同特征。我们的结果为血管生成过程提供了新颖的见解,并确定了抗血管生成疗法的新潜在靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号